HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma

NCT07697339 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Len
DRUG: Rituximab plus lenalidomide
DRUG: Phase Ib Cohort 2: HDM2005 1.4 mg/kg + R-Len
DRUG: HDM2005 plus rituximab and lenalidomide

Sponsor

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.